HomeCompareSHXWF vs ABBV

SHXWF vs ABBV: Dividend Comparison 2026

SHXWF yields 6.28% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SHXWF wins by $7820.05M in total portfolio value
10 years
SHXWF
SHXWF
● Live price
6.28%
Share price
$1.33
Annual div
$0.08
5Y div CAGR
94.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7820.15M
Annual income
$7,520,671,518.10
Full SHXWF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SHXWF vs ABBV

📍 SHXWF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSHXWFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SHXWF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SHXWF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SHXWF
Annual income on $10K today (after 15% tax)
$533.65/yr
After 10yr DRIP, annual income (after tax)
$6,392,570,790.39/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, SHXWF beats the other by $6,392,549,734.38/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SHXWF + ABBV for your $10,000?

SHXWF: 50%ABBV: 50%
100% ABBV50/50100% SHXWF
Portfolio after 10yr
$3910.13M
Annual income
$3,760,348,144.93/yr
Blended yield
96.17%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SHXWF
No analyst data
Altman Z
2.3
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SHXWF buys
0
ABBV buys
0
No recent congressional trades found for SHXWF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSHXWFABBV
Forward yield6.28%3.06%
Annual dividend / share$0.08$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR94.8%40.6%
Portfolio after 10y$7820.15M$102.3K
Annual income after 10y$7,520,671,518.10$24,771.77
Total dividends collected$7799.14M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SHXWF vs ABBV ($10,000, DRIP)

YearSHXWF PortfolioSHXWF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,923$1,222.99$11,550$430.00+$373.00SHXWF
2$15,412$2,654.69$13,472$627.96+$1.9KSHXWF
3$22,739$6,247.42$15,906$926.08+$6.8KSHXWF
4$41,111$16,780.39$19,071$1,382.55+$22.0KSHXWF
5$99,221$55,232.99$23,302$2,095.81+$75.9KSHXWF
6$348,858$242,691.53$29,150$3,237.93+$319.7KSHXWF
7$1,926,751$1,553,472.80$37,536$5,121.41+$1.89MSHXWF
8$17,681,776$15,620,152.27$50,079$8,338.38+$17.63MSHXWF
9$279,889,545$260,970,044.16$69,753$14,065.80+$279.82MSHXWF
10$7,820,153,331$7,520,671,518.10$102,337$24,771.77+$7820.05MSHXWF

SHXWF vs ABBV: Complete Analysis 2026

SHXWFStock

Xinhua Winshare Publishing and Media Co., Ltd., together with its subsidiaries, engages in the publishing and distribution businesses in the People's Republic of China. The company operates in two segments, Publication and Distribution. The Publication segment publishes books, journals, audio-visual products, and digital products; provides printing services; and supplies printing materials. The Distribution segment distributes textbooks and supplementary materials to schools, teachers, and students; and supplies education informatization and equipment services for primary and secondary schools, as well as engages in the retail, distribution, and online sale of publications. The company also sells books, newspapers, journals, artwork, and electronic equipment, as well as electronic publications; produces audio and video tapes; and provides logistics, assets management, education ancillary, and business services. In addition, it is involved in the wholesale and retail of pre-packaged food and dairy products; import and export business; property leasing; catering and ticket agency; and advertising agency and leasing business. Further, the company engages in the wholesale and retail distribution of goods; project investment and management; and organizing and planning of cultural and art exchange activities. Additionally, it offers computer software development and system services; business consulting; travel agency and related services; study tour event planning, conference, and exhibition services. The company was formerly known as Sichuan Xinhua Winshare Chainstore Co., Ltd. and changed its name to Xinhua Winshare Publishing and Media Co., Ltd. in 2010. The company was founded in 2005 and is headquartered in Chengdu, the People's Republic of China. Xinhua Winshare Publishing and Media Co., Ltd. is a subsidiary of Sichuan Xinhua Publishing and Distribution Group Co., Ltd.

Full SHXWF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SHXWF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SHXWF vs SCHDSHXWF vs JEPISHXWF vs OSHXWF vs KOSHXWF vs MAINSHXWF vs JNJSHXWF vs MRKSHXWF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.